Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 7/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612537 | 0.86 | OPRD1 (0.48) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL4615941 | 0.86 | OPRK1 (0.51) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL4913216 | 0.86 | TSHR (0.45) | OPRK1OPRD1 | |
| SCHEMBL14046321 | 0.82 | KMT2A (0.54) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL14046325 | 0.82 | KMT2A (0.54) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL14046294 | 0.82 | KMT2A (0.54) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL4913221 | 0.80 | OPRD1 (0.43) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL18038731 | 0.79 | OPRL1 (0.59) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL28063989 | 0.78 | OPRK1 (0.56) | OPRK1OPRD1ALDH1A1KMT2AMAPT | |
| SCHEMBL2246366 | 0.77 | OPRK1 (0.49) | OPRK1OPRD1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | OPRK1 24/4885OPRD1 8/4885ALDH1A1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.